These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Scholz T; Zhao L; Temmler U; Bath P; Heptinstall S; Lösche W Platelets; 2002 Nov; 13(7):401-6. PubMed ID: 12487787 [TBL] [Abstract][Full Text] [Related]
3. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets. Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439 [TBL] [Abstract][Full Text] [Related]
4. P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist. Zhao L; Bath PM; May J; Lösche W; Heptinstall S Platelets; 2003; 14(7-8):473-80. PubMed ID: 14713516 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of fibrinogen binding and surface recruitment of GpIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852. Wittig K; Rothe G; Schmitz G Thromb Haemost; 1998 Mar; 79(3):625-30. PubMed ID: 9531053 [TBL] [Abstract][Full Text] [Related]
6. The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Zhao L; Bath PM; Fox S; May J; Judge H; Lösche W; Heptinstall S Curr Med Res Opin; 2003; 19(3):178-86. PubMed ID: 12803731 [TBL] [Abstract][Full Text] [Related]
7. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors. Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249 [TBL] [Abstract][Full Text] [Related]
8. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. Gremmel T; Eslam RB; Koppensteiner R; Lang IM; Panzer S Cardiovasc Ther; 2013 Oct; 31(5):e40-5. PubMed ID: 23311679 [TBL] [Abstract][Full Text] [Related]
15. Discovery of an orally active non-peptide fibrinogen receptor antagonist. Stilz HU; Jablonka B; Just M; Knolle J; Paulus EF; Zoller G J Med Chem; 1996 May; 39(11):2118-22. PubMed ID: 8667355 [No Abstract] [Full Text] [Related]
16. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Steiner S; Seidinger D; Huber K; Kaun C; Minar E; Kopp CW Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1697-702. PubMed ID: 12869353 [TBL] [Abstract][Full Text] [Related]
17. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor. Xiao Z; Théroux P; Frojmovic M Thromb Haemost; 1999 Feb; 81(2):281-5. PubMed ID: 10064007 [TBL] [Abstract][Full Text] [Related]
19. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation. Straub A; Wendel HP; Azevedo R; Ziemer G Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360 [TBL] [Abstract][Full Text] [Related]
20. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions]. Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720 [No Abstract] [Full Text] [Related] [Next] [New Search]